Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 12, 2018 at 12:12 AM.

  1. #1 cafead, Dec 12, 2018 at 12:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company's first doublet has performed modestly on the market compared to a key rival's three-drug regimen.

    article source
     
    Quote

Reply to Thread